title: Effect of topical aqueous suppression on intraocular gas duration after pure perfluoropropane injection in nonvitrectomized eyes with retinal detachment.
abstract: OBJECTIVE
  To determine whether topical aqueous suppressants affect the duration of pure expansile intraocular gas in nonvitrectomized eyes.
  
  
  METHODS
  A prospective randomized controlled trial was performed on nonvitrectomized patients undergoing retinal detachment repair with scleral buckle or pneumatic retinopexy using 0.3 mL of 100% perfluoropropane (C3F8) gas tamponade. Eyes were randomly assigned to receive topical dorzolamide 2% and timolol 0.5% twice daily postoperatively until gas dissolution or to observation.
  
  
  RESULTS
  Twenty-one patients met all inclusion and exclusion criteria. Twelve were randomized to the control group and nine to the dorzolamide-timolol group. In the dorzolamide-timolol group, mean intraocular pressure was 17.4 on postoperative Day 1 and 12.5 on postoperative Week 1 (P = 0.03). In the control group, mean intraocular pressure was 14.5 on postoperative Day 1 and 15.1 on postoperative Week 1 (P = 0.73). The mean duration of C3F8 was 37.8 days in the dorzolamide-timolol group and 40.4 days in the control group (P = 0.70).
  
  
  CONCLUSIONS
  Topical aqueous suppression does not seem to have a significant effect on the duration of pure expansile intraocular C3F8 in nonvitrectomized eyes after pneumatic retinopexy or scleral buckling.
authors: *Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania; and †Retina Consultants San Diego, San Diego, California.
authors: Jason
authors: J
authors: Hsu
authors: Adam T
authors: AT
authors: Gerstenblith
authors: Nikolas J S
authors: NJ
authors: London
authors: Sunir J
authors: SJ
authors: Garg
authors: Marc J
authors: MJ
authors: Spirn
authors: Joseph I
authors: JI
authors: Maguire
authors: Carl
authors: C
authors: Park
authors: Arunan
authors: A
authors: Sivalingam
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001082:Aqueous Humor / Q000187:drug effects*; D017679:Cryotherapy; D004338:Drug Combinations; D058450:Endotamponade; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D056965:Injections, Intraocular; D007429:Intraocular Pressure / Q000187:drug effects; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D012163:Retinal Detachment / Q000601:surgery*; D012591:Scleral Buckling; D013449:Sulfonamides / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D013997:Time Factors; D013999:Timolol / Q000494:pharmacology; D014821:Vitrectomy
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D005466:Fluorocarbons; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; C062765:dorzolamide; C042852:perflutren